Search

Background: Early left ventricular systolic dysfunction is common after moderate-severe traumatic brain injury (TBI). Echocardiography (Echo) can evaluate cardiac function across various clinical scenarios; however, its utilization in isolated TBI remains poorly understood. To address this gap, we aim to examine Echo utilization in hospitalized adults with isolated TBI., Methods: Using a propensity-matched cohort based on All Patient Refined Diagnosis Related Group severity of illness, we performed a multivariable logistic regression analysis (adjusting for demographics, admitting hospital characteristics, TBI characteristics, cardiac comorbidities, and cardiac complications) to examine factors associated with Echo utilization in patients with isolated TBI in the US National Inpatient Sample (2016-2020). We reported adjusted odds ratio (aOR) and 95% confidence intervals., Results: In 4874 patients matched by APR-DRG severity of illness, the factors associated with Echo utilization were as follows: Older age compared to 18-44 years, Urban teaching hospital: aOR 1.44 [1.05;1.98], TBI associated with syncope: 3.29 [2.68;4.07], ICP monitoring: 2.26 [1.18, 4.45), hypertension: 1.35 [1.18, 1.54], myocardial infarction: 2.89 [2.14, 3.94], atrial fibrillation:1.38 [1.10, 1.74], heart failure: 1.57 [1.31, 1.87], ventricular tachycardia: 1.85 [1.28, 2.71), and pulmonary embolism: 2.61 [1.51, 4.66]., Conclusions: Echo utilization was associated with TBI etiology, pre-existing cardiac comorbidities, and in-hospital cardiac complications. These findings need validation in prospective studies., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2025 Elsevier Ltd. All rights reserved.)

Background: We implemented a quality improvement project to transition from routine cerebrospinal fluid (CSF) sampling to indication-based sampling in aneurysmal subarachnoid hemorrhage (aSAH) patients with an external ventricular drain (EVD)., Methods: Forty-seven patients were assessed across 2 epochs: routine (n=22) and indication-based (n=25) CSF sampling. The primary outcome was the number of CSF samples, and secondary outcomes included cost reductions and ventriculostomy-associated infections., Results: Patient characteristics were similar in the routine and indication-based sampling groups, as was the mean (SD) EVD duration (13.86 [5.28] days vs. 12.44 [4.78] days, respectively; P=0.936). One hundred eight CSF samples were collected during the quality improvement project; 81 in the routine sampling period and 27 in the indication-based sampling period. The median (interquartile range) CSF sampling rate reduced from 4 (3 to 4) per patient during routine sampling to 1 (0 to 2) during indication-based sampling (odds ratio: 0.19; 95% CI: 0.08-0.46; P<0.001), representing a 73% reduction in the number of samples after the transition to indication-based sampling. Each CSF sample cost $723, resulting in total sampling costs in the routine and indication-based sampling periods of $58,571 and $19,524, respectively. Therefore, the mean cost per patient was significantly higher in the routine sampling period than in the indication-based period ($2772 [$615] vs. $889 [$165], respectively; P=0.007). There were no ventriculostomy-associated infections in either period., Conclusion: Transitioning from routine to indication-based CSF sampling in aSAH patients with an EVD reduced sampling frequency and associated costs without increasing infection rates., Competing Interests: M.R.L. reports unrestricted educational grants from Medtronic and Stryker; equity interest in Proprio, Synchron, Hyperion Surgical, Stroke Diagnostics, Fluid Biomed, Apertur; consulting for Aeaean Advisers, Metis Innovative, Stereotaxis, Genomadix; data safety monitoring board of Arsenal Medical; editorial board of Journal of NeuroInterventional Surgery. A.V.L. reports receiving salary support from LifeCenter Northwest. The remaining authors have no conflicts of interest to declare., (Copyright © 2025 Wolters Kluwer Health, Inc. All rights reserved.)

Purpose of Review: We examine what is known, what is new, and what is emerging in acute neurotrauma relevant to the anesthesiologist., Recent Findings: Timely and goal-directed care is critical for all patients requiring urgent/emergent anesthesia care. Anesthesia care for acute neurological injury should incorporate understanding the evolution of traumatic brain injury and spinal cord injury that translates to preoperative preparation, hemodynamic resuscitation, prevention of second insults, and safe transport between care settings. Anesthesia care should support optimizing patient outcomes., Summary: Best practices involve extrapolating data from the intensive care unit setting since there is a lack of research addressing anesthesia care for acute neurological injury. There are opportunities to generate data to support evidence-based anesthetic care., Competing Interests: Conflicts of Interest The authors declare no competing interests.

Background: Intraoperative events and clinical management of deceased organ donors after brain death are poorly characterized and may consequently vary between hospitals and organ procurement organization (OPO) regions. In a multicenter cohort, we sought to estimate the incidence of hypotension and anesthetic and nonanesthetic medication use during organ recovery procedures., Methods: We used data from electronic anesthetic records generated during organ recovery procedures from brain-dead adults across a Multicenter Perioperative Outcomes Group (MPOG) cohort of 14 US hospitals and 4 OPO regions (2014-2020). Hypotension, defined as mean arterial pressure or MAP <60 mm Hg for at least 10 cumulative minutes was the primary outcome of interest. The associations between hypotension and age, sex, race, anesthesia time, OPOs, and OPO case volume were examined using multivariable mixed-effects Poisson regression analyses with robust standard error estimates. We calculated intraclass correlation coefficients (ICCs) to describe the variation between-MPOG centers and the OPO regions in the use of medications, time of the operation, and duration of the operation., Results: We examined 1338 brain-dead adult donors, with a mean age of 42± (standard deviation [SD] 15) years; 60% (n = 801) were males and 67% (n = 891) non-Hispanic White. During the entire intraoperative monitoring period, 321 donors (24%, 95% confidence interval [CI], 22%-26%) had hypotension for a median of 13.8% [quartile1-quartile 3: 9.4%-21%] of the monitoring period and a minimum of 10 minutes to a maximum of 96 minutes [(median: 17, quartile1-quartile 3: 12-24]). The probability having hypotension in donors 35 to 64 years and 65 years and older were approximately 30% less than in donors 18 to 34 years of age (adjusted relative risk ratios, aRR, 0.68, 95% CI, 0.55-0.82, aRR, 0.63, 95% CI, 0.42-0.94, respectively). Donors received intravenous heparin (96.4%, n = 1291), neuromuscular blockers (89.5%, n = 1198), vasoactive medications (82.7%, n = 1108), crystalloids (76.2%, n = 1020), halogenated anesthetic gases (63.5%, n = 850), diuretics (43.8%, n = 587), steroids (16.7%, n = 224), and opioids (23.2%, n = 310). The largest practice heterogeneity observed between the MPOG center and OPO regions was steroids (between-center ICCs = 0.65, 95% CI, 0.62-0.75, between-region ICCs = 0.39, 95% CI, 0.27-0.63) and diuretics (between-center ICCs = 0.44, 95% CI, 0.36-0.6, between-region ICCs = 0.30, 95% CI, 0.22-0.49)., Conclusions: Despite guidelines recommending maintenance of MAP >60 mm Hg in adult brain-dead organ donors, hypotension during recovery procedures was common. Future research is needed to clarify the relationship between intraoperative events with donation and transplantation outcomes and to identify best practices for the anesthetic management of brain-dead donors in the operating room., Competing Interests: Conflicts of Interest: See Disclosures at the end of the article., (Copyright © 2024 International Anesthesia Research Society.)

Background: Key goals during intracranial surgery are to facilitate rapid emergence and extubation for early neurologic evaluation. Longer-acting opioids are often avoided or administered at subtherapeutic doses due to their perceived risk of sedation and delayed emergence. However, inadequate analgesia and increased postoperative pain are common after intracranial surgery. In this multicenter study, we describe variability in opioid and nonopioid administration patterns in patients undergoing intracranial surgery., Methods: This was a multicenter, retrospective observational cohort study using the Multicenter Perioperative Outcomes Group database. Opioid and nonopioid practice patterns in 31,217 cases undergoing intracranial surgery across 11 institutions in the United States are described., Results: Across all 11 institutions, total median [interquartile range] oral morphine equivalents, normalized to weight and anesthesia duration was 0.17 (0.08 to 0.3) mg.kg.min -1 . There was a 7-fold difference in oral morphine equivalents between the lowest (0.05 [0.02 to 0.13] mg.kg.min -1 ) and highest (0.36 [0.18 to 0.54] mg.kg.min -1 ) prescribing institutions. Patients undergoing supratentorial surgery had higher normalized oral morphine equivalents compared with those having infratentorial surgery [0.17 [0.08-0.31] vs. 0.15 [0.07-0.27] mg/kg/min -1 ; P <0.001); however, this difference is clinically small. Nonopioid analgesics were not administered in 20% to 96.8% of cases across institutions., Conclusion: This study found wide variability for both opioid and nonopioid utilization at an institutional level. Future work on practitioner-level opioid and nonopioid use and its impact on outcomes after intracranial surgery should be conducted., Competing Interests: A.V.L. reports salary support from LifeCenter Northwest. P.V. receives support from Blue Cross Blue Shield of Michigan. E.S. is supported by a grant from the National Institute on Drug Abuse (K08DA042314) and reports consulting fees unrelated to this work from Analysis Group, Inc. and Lucid Lane, LLC. D.A.C. is supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under award number K08HL159327. D.A.C. declares research support from Merck & Co. paid to the University of Michigan, unrelated to the presented work in the financial section. B.I.N. is a JNA Editorial Board member. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The remaining authors have no conflicts of interest to declare., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)